Clinical trials: Choroidal Diseases
Choroideremia
The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study
Choroideremia (CHM) is an inherited retinal disorder that causes progressive vision loss, ultimately leading to complete blindness.
- Trial name
- DARC (NCT05045703)
- Testing
- Vitamin A palmitate
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duke University
Choroidal Neovascularization
Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
The objectives of this study are to investigate the safety and effectiveness of EYLEA.
- Trial name
- NCT02260687
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 353 people
- Sponsor
- Bayer
Retinal Vein Occlusion
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the…
- Trial name
- NCT01580020
- Testing
- RFB002, Dexamethasone
- Where
- 37 sites in Germany
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Age-related Macular Degeneration
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
- Trial name
- NCT00251459
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 5,000 people
- Sponsor
- Genentech, Inc.
Uveal Melanoma, Ocular Melanoma
Study in Subjects With Small Primary Choroidal Melanoma
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with…
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT03052127
- Testing
- Light-activated AU-011, Laser Activation
- Where
- 13 sites in United States
- Volunteers
- 57 people
- Sponsor
- Aura Biosciences
Epiretinal Membrane
Choroidal Thickness Vitrectomy
The purpose of this study is to assess the influence of vitrectomy on changes in central choroidea and comparing the results in imaging of the choroidea with two different OCT devices.
- Trial name
- NCT02617147
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Medical University of Vienna
Primary Open Angle Glaucoma
Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma
The present study is designed to compare the response of choroidal blood flow to the hand-grip test in glaucoma patients with and without visual field progression.
- Trial name
- NCT00284440
- Where
- Switzerland
- Sponsor
- University Hospital, Basel, Switzerland
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open Angle Glaucoma
The Effects of an Antioxidant Formulation on Ocular Blood Flow
The objective is to evaluate the effects of an antioxidant formula versus placebo on ocular blood flow in a randomized double-blind, crossover design.
- Trial name
- NCT01930487
- Testing
- dietary supplement with antioxidants
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- ScienceBased Health
Choroidal Neovascularization in Angioid Streaks
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).
Angioid streaks are rare lesions associated to retinal pigment epithelium degenerations. They can be caused by general diseases as pseudoxanthoma elasticum, Paget's disease or drepanocytosis.
- Trial name
- ASTRID (NCT02573038)
- Testing
- Aflibercept
- Sponsor
- Hospices Civils de Lyon
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus
Clinical and Histopathologic Characteristics of BAP1 Mutations
The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen…
- Conditions
- Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM)
- Trial name
- NCT01773655
- Testing
- tumor specimens
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT05099094
- Testing
- BD311
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Myopia Progression, Axial Length, Eye
Low Dose Atropine Eye Drops in Myopic Egyptian Children
Previous Studies reported that low concentration atropine eye drops may be effective in increasing the choroidal blood flow and thickness and this slows myopia progression.
- Conditions
- Myopia Progression, Axial Length, Eye, Sclera Thickness
- Trial name
- LAMP (NCT06265454)
- Testing
- low dose atropine eye drops
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Ain Shams University
Myopic Macular Haemorrhages
Myopic Macular Haemorrhages
1. To identify the underlying causes of macular haemorrhages in patients with high myopia 2. In the eyes found to have macular haemorrhages secondary to choroidal neovascularisation, we hope to identify the risk factors for the…
- Trial name
- NCT00345228
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore National Eye Centre
Delirium
Cerebral Blood Flow During CPB During Cardiac Surgery and the Presence of Post op Delirium
Cardiac surgery is associated with multiple events and issues that increase risk for adverse postoperative neurological outcomes including postoperative cognitive dysfunction.
- Trial name
- NCT02084394
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Johns Hopkins University
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Pigment Epithelial Detachment
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
- Trial name
- NCT00749021
- Testing
- Ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Clement K. Chan
Age Related Macular Degeneration, Choroidal Neovascularization
Efficacy of Retreatments With Intravitreal Bevacizumab
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual…
- Trial name
- NCT00406744
- Testing
- Intravitreal injection of Bevacizumab
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Macular Degeneration
Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration (AMD) who are receiving photodynamic therapy, or PDT…
- Trial name
- NCT00043680
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Eye Institute (NEI)